ClinicalTrials.Veeva

Menu

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK)

U

Universidade do Porto

Status

Enrolling

Conditions

Fabry Disease

Treatments

Diagnostic Test: Alfa-galactosidase activity and genetic testing for Fabry diagnosis

Study type

Observational

Funder types

Other

Identifiers

NCT05409846
F-CHECK

Details and patient eligibility

About

In Portugal, the prevalence of Fabry disease is largely unknown as recently has been stressed by the Portuguese hypertrophic cardiomyopathy registry investigators.

On the other hand, few data on Fabry screening protocols in patients with compromised ejection fraction including burned-out hypertrophic cardiomyopathy series have been published.

This project intends to perform screening of Fabry disease in patients with distinct cardiomyopathy phenotypes of unknown or dubious etiology and explore the less knew impact of the disease in other cardiac phenotypes.

Enrollment

600 estimated patients

Sex

All

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with heart disease diagnosed after the age of 30:

  • unexplained hypertrophic cardiomyopathy (Group A)
  • unexplained left ventricle hypertrophy confirmed in two different examinations using the same or different imaging methods (Group B)
  • unexplained burned-out hypertrophic cardiomyopathy (Group C)
  • unexplained dilated cardiomyopathy with evidence of late gadolinium enhancement involving the basal posterolateral wall segments (Group D)

Exclusion criteria

  • previous exclusion of Fabry disease
  • previous identified causal pathogenic/likely pathogenic genetic variant
  • evidence of cardiomyopathy under the age of 30

Trial design

600 participants in 4 patient groups

Group A
Description:
Idiopathic hypertrophic cardiomyopathy
Treatment:
Diagnostic Test: Alfa-galactosidase activity and genetic testing for Fabry diagnosis
Group B
Description:
Idiopathic left ventricle hypertrophy
Treatment:
Diagnostic Test: Alfa-galactosidase activity and genetic testing for Fabry diagnosis
Group C
Description:
Idiopathic burned-out hypertrophic cardiomyopathy
Treatment:
Diagnostic Test: Alfa-galactosidase activity and genetic testing for Fabry diagnosis
Group D
Description:
Idiopathic dilated cardiomyopathy
Treatment:
Diagnostic Test: Alfa-galactosidase activity and genetic testing for Fabry diagnosis

Trial contacts and locations

15

Loading...

Central trial contact

Elisabete Martins, MD, PhD; Janete Santos, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems